Merck Serono pulls out of MediCult bid
Merck Serono, the Swiss division of Germany's Merck KGaA, confirms its commitment to investing in the therapeutic area of fertility, after the parent company informed the Oslo, Norway, Stock Exchange of its withdrawal of the voluntary cash tender offer for MediCult A/S, a leader in assisted reproductive technologies, as the required share threshold was not reached in the set timeframe.
"Merck Serono has a proud heritage of leadership in the field of fertility and will actively pursue opportunities that will contribute to bring further innovation to physicians and patients, and increase the success rate of fertility treatments," said Richard Douge, executive vice president, global marketing, at Merck Serono.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze